A Phase 2 Multi-center, Randomized, Double Blind, Placebo-controlled, Parallel Group Study to Evaluate the Efficacy and Safety of T-817MA in Patients With Mild to Moderate Alzheimer's Disease
Phase of Trial: Phase II
Latest Information Update: 19 Jul 2017
At a glance
- Drugs Edonerpic (Primary)
- Indications Alzheimer's disease
- Focus Therapeutic Use
- Sponsors Toyama Chemical
- 19 Jul 2017 Results published in a FUJIFILM Corporation Media Release.
- 19 Jul 2017 Primary endpoint has not been met. (The primary objective is to evaluate the efficacy of T-817MA as measured by ADAS-cog and ADCS-CGIC., according to a FUJIFILM Corporation media release.
- 16 May 2017 Status changed from active, no longer recruiting to completed.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History